Non-NSAID pharmacologic treatment options for the management of chronic pain

American Journal of Medicine

Volumn 105, Issue 1 B, 1998, Pages 45S-52S

  Schnitzer, Thomas J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; DEXTROPROPOXYPHENE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMADOL;

CHRONIC PAIN; CONFERENCE PAPER; GASTROINTESTINAL DISEASE; HUMAN; NEPHROTOXICITY; PAIN ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT INDICATION;

EID: 0032572518     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00073-4     Document Type: Conference Paper

References (54)

1. Flynn BL. Rheumatoid arthritis and osteoarthritis: current and future therapies. Am Pharm. 1994;34:1-8.
2. Caudill MA, Holman GH, Turk D. Effective ways to manage chronic pain. Patient Care. June 1996:154-172.
3. Conaway DC. Using NSAIDs safely in the elderly. Hosp Med. May 1995;31(5):23-34.
4. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114: 257-263.
5. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 1993;105: 1078-1088.
6. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991; 31:588-598.
7. Muir H. Current and future trends in articular cartilage research and osteoarthritis. In: Kuertner KE, Schleyerbach R, Hascall VC, eds. Articular Cartilage Biochemistry. New York: Raven Press; 1986:423-440.
8. Bayliss MT. Proteoglycan structure in normal and osteoarthrotic human cartilage. In: Kuertner KE, Schleyerbach R, Hascall VC, eds. Articular Cartilage Biochemistry. New York: Raven Press; 1986:295-310.
9. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I: osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum. 1995;38:1535-1540.
10. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II: osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541-1546.
11. Bradley JD, Brandt KD, Katz BP, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol. 1992;19:1550-1554.
12. Schnitzer TJ. Osteoarthritis treatment update. Minimizing pain while limiting patient risk. Postgrad Med. 1993;93:89-92.
13. Schnitzer TJ, Andriachhi TP, Fedder D, et al. Effect of NSAIDs on knee loading in patients with osteoarthritis. (Abstr.) Arthritis Rheum. 1990;33:592.
14. Ghosh P. Anti-rheumatic drugs and cartilage. Baillieres Clin Rheumatol. 1980;19:212-217.
15. Williams HJ, Ward JR, Egger JM, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993; 36:1196-1206.
16. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature. 1972:240:410-411.
17. Physician's Desk Reference. 51st ed. Montvale, NJ: Medical Economics Company, 1997:1570-1571.
18. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis. 1990;10;267-278.
19. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87-91.
20. Vickers FN. Mucosal effects of aspirin and acetaminophen: report of a controlled gastroscopic study. Gastrointest Endose. 1967;14:94-99.
21. Henrich WL, Agodos LE, Barrett B. Analgesics and the kidney: summary and recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27:162-165.
22. Johnston SC, Pelletier LL Jr. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Medicine. 1997;76:185-191.
23. Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med. 1997;337:1112-1117.
24. Benson GD. Hepatotoxicity following the therapeutic use of antipyretic analgesics. Am J Med. 1983;75:85-93.
25. Forrest JAH, Adriaenssens P, Finlayson NDC, Prescott LF. Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol. 1979;15:427-431.
26. Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand. 1979;624(suppl):99-105.
27. Gabrielle L, Leterrier F, Molinie C, et al. Determination of human liver cytochrome P-450 by a micromethod using electron paramagnetic resonance. Study of 141 liver biopsies. Gastroenterol Clin Biol. 1977;1:775-782.
28. Farrell GC, Cooksley WGE, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther. 1979;26:483-492.
29. Forrest JAH, Finlayson NDC, Adjepon-Yamoah KK, Prescott LF. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. BMJ. 1977;1:1384-1387.
30. Shamszad M, Soloman H, Mobarhan S, Iber FL. Abnormal metabolism of acetaminophen in patients with alcoholic liver disease. (Abstr.) Gastroenterology. 1975;A-65:865.
31. Amman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg). 1978;25: 283-286.
32. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther. 1992; 260:275-285.
33. Driessen B, Reimann W, Giertz H. Effect of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol. 1993;108: 806-811.
34. Katz WA. The role of tramadol in the management of musculoskeletal pain. Today's Ther Trends. 1995;13:177-186.
35. Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993;267: 331-340.
36. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Company; 1997:1594-1599.
37. Dalgin P. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis. Presented at the National Scientific Meeting, American College of Rheumatology; November 8-12, 1997; Washington, DC.
38. Roth SH. Efficacy and safety of tramadol HCI in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. Forthcoming 1998;25 (in press).
39. Schnitzer T, Kamin M. Ultram® (tramadol HCI) maintains relief of osteoarthritis (OA) pain when substituted for high dose naproxen. Presented at the National Scientific Meeting, the American College of Rheumatology; November 8-12, 1997; Washington, DC.
40. Russell IJ, Kamin M, Sager D, et al. Efficacy of Ultram® (tramadol HCI) treatment of fibromyalgia syndrome: preliminary analysis of a multi-center, randomized, placebo-controlled study. Presented at the National Scientific Meeting, American College of Rheumatology; November 8-12, 1997; Washington, DC.
41. Dalgin PH. Use of tramadol in chronic pain. Clin Geriatr. 1995;3:17-30.
42. Barkin RL. Alternative dosing for tramadol aids effectiveness. Formulary. 1995;30:542-543.
43. Ruoff G. An evaluation of varying titration rates of tramadol in patients with chronic joint pain. Pharmacotherapy. 1998 (in press).
44. Grover H. Propoxyphene. J Indian Med Assoc. 1988;86:21-23.
45. US GAO Report to the Honorable Ron Wyden, House of Representatives: Prescription Drugs and the Elderly. GAO/ HEHS-95-152. US General Accounting Office, Health Education and Human Services Division, July 1995.
46. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA. 1994;272:292-296.
47. Mapp P, Kidd B. The role of substance P in rheumatic disease. Semin Arthritis Rheum. 1994;23(suppl):3-9.
48. Lotz M. Experimental models of arthritis: identification of substance P as a therapeutic target and use of capsaicin to manage joint pain and inflammation. Semin Arthritis Rheum. 1994;23(suppl):10-17.
49. Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther. 1991;13:383-395.
50. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol. 1992;19:604-607.
51. Schnitzer TJ, Morton C, Coker S. Topical capsaicin therapy for osteoarthritis pain: achieving a maintenance regimen. Semin Arthritis Rheum. 1994;23(suppl):34-40.
52. Altman RD, Aven A, Holmburg CE, et al. Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum. 1994;23(suppl):25-33.
53. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol. 1994;46:517-522.
54. Tolman KG. Hepatotoxicity of non-narcotic analgesics. Am J Med 1998;105(suppl):13-19.